Kevin Luciani

Document Type

Honors Thesis


Alzheimer’s disease (AD) is a neurological condition that accounts for 60 to 70% of dementia. The neurotransmitter acetylcholine is thought to play a fundamental role in the propagation of memory and is a neurotransmitter of great importance in AD. Another neurotransmitter involved in the treatment of AD is glutamate via the NMDA receptor. While cholinergic medications and NDMA antagonists are available for the treatment of AD there remains a need to develop different medications that are more effectual for certain individuals My objective is to design pharmacologically active molecules to treat AD by utilizing knowledge of neuropharmacology, computational techniques, and the literature in order to generate molecules that have applications to better treat Alzheimer’s disease by modifying functional groups to increase receptor efficacy and affinity. Computational models demonstrated greater receptor affinity compared to currently available AD drugs. This shows that these compounds might be potentially useful in treating AD.

Publication Date






To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.